CEBD Coronavirus Dermatology Resource
Journal articles - Hydroxychloroquine, chloroquine, antibiotics & other coronavirus treatments, and vaccines
[Selected articles of dermatological relevance]
Extraordinary claims without extraordinary evidence controversy on anti-androgen therapy for COVID-19.
Trüeb RM, Régnier A, Caballero-Uribe N, Dias MFRG, Dutra Rezende H.
J Eur Acad Dermatol Venereol. 2021 Mar 30. doi: 10.1111/jdv.17249. Online ahead of print. Commentary.
https://doi.org/10.1111/jdv.17249
Skin manifestations of the BNT162b2 mRNA COVID-19 vaccine in healthcare workers. "COVID-arm": a clinical and histological characterization.
Fernandez-Nieto D, Hammerle J, Fernandez-Escribano M, Moreno-Del Real CM, Garcia-Abellas P, Carretero-Barrio I, Solano-Solares E, de-la-Hoz-Caballer B, Jimenez-Cauhe J, Ortega-Quijano D, Fernandez-Guarino M.
J Eur Acad Dermatol Venereol. 2021 Mar 30. doi: 10.1111/jdv.17250. Online ahead of print. Cohort / registry study.
https://doi.org/10.1111/jdv.17250
Persistent maculopapular rash after the first dose of Pfizer-BioNTech COVID-19 vaccine.
Ackerman M, Henry D, Finon A, Binois R, Esteve E.
J Eur Acad Dermatol Venereol. 2021 Mar 30. doi: 10.1111/jdv.17248. Online ahead of print. Case report.
https://doi.org/10.1111/jdv.17248
Polyethylene glycol and polysorbate skin testing in the evaluation of COVID-19 vaccine reactions: Early report.
Pitlick MM, Sitek AN, Kinate SA, Joshi AY, Park MA.
Ann Allergy Asthma Immunol. 2021 Mar 25:S1081-1206(21)00188-5. doi: 10.1016/j.anai.2021.03.012. Online ahead of print. Case series.
https://doi.org/10.1016/j.anai.2021.03.012
Vaccination against SARS-COV-2 and psoriasis: The three things every dermatologist should know.
Diotallevi F, Campanati A, Radi G, Martina E, Rizzetto G, Barbadoro P, D'Errico MM, Offidani A.
J Eur Acad Dermatol Venereol. 2021 Mar 29. doi: 10.1111/jdv.17256. Online ahead of print. Review / commentary.
https://doi.org/10.1111/jdv.17256
COVID-19 "second wave" and vaccines: the dermatologists' perspective.
Burlando M, Russo R, Cozzani E, Parodi A.
Int J Dermatol. 2021 Mar 25. doi: 10.1111/ijd.15547. Online ahead of print. Commentary.
https://doi.org/10.1111/ijd.15547
Risk of severe allergic reactions to COVID-19 vaccines among patients with allergic skin diseases - practical recommendations. A position statement of ETFAD with external experts.
Ring J, Worm M, Wollenberg A, Thyssen JP, Jakob T, Klimek L, Bangert C, Barbarot S, Bieber T, de Bruin-Weller MS, Chernyshov PV, Christen-Zaech S, Cork M, Darsow U, Flohr C, Fölster-Holst R, Gelmetti C, Gieler U, Gutermuth J, Heratizadeh A, Hijnen DJ, von Kobyletzki LB, Kunz B, Paul C, De Raeve, Seneschal J, Simon D, Spuls PI, Stalder JF, Svensson A, Szalai Z, Taieb A, Torrelo A, Trzeciak M, Vestergaard, Werfel T, Weidinger S, Deleuran M.
J Eur Acad Dermatol Venereol. 2021 Mar 22. doi: 10.1111/jdv.17237. Online ahead of print. Review & recommendations.
https://doi.org/10.1111/jdv.17237
"COVID arm": A reaction to the Moderna vaccine.
Wei N, Fishman M, Wattenberg D, Gordon M, Lebwohl M.
JAAD Case Rep. 2021 Feb 25. doi: 10.1016/j.jdcr.2021.02.014. Online ahead of print. Case report.
https://doi.org/10.1016/j.jdcr.2021.02.014
Prompt onset of erythema multiforme following the first BNT162b2 SARS-CoV-2 vaccination.
Gambichler T, Scholl L, Ocker L, Stranzenbach R.
J Eur Acad Dermatol Venereol. 2021 Mar 16. doi: 10.1111/jdv.17225. Online ahead of print. Case report.
https://doi.org/10.1111/jdv.17225
Lichen planus arising after COVID-19 vaccination.
Hiltun I, Sarriugarte J, Martínez-de-Espronceda I, Garcés A, Llanos C, Vives R, Yanguas JI.
J Eur Acad Dermatol Venereol. 2021 Mar 16. doi: 10.1111/jdv.17221. Online ahead of print. Case report.
https://doi.org/10.1111/jdv.17221
Oral angiotensin converting enzyme inhibitors for the treatment of delayed inflammatory reaction of dermal hyaluronic acid fillers following COVID-19 vaccination - A model for inhibition of angiotensin II-induced cutaneous inflammation.
Munavalli GG, Knutsen-Larson S, Lupo MP, Geronemus RG.
JAAD Case Rep. 2021 Mar 2. doi: 10.1016/j.jdcr.2021.02.018. Online ahead of print.
https://doi.org/10.1016/j.jdcr.2021.02.018
Coronavirus vaccination adverse reactions and the role of the dermatologist.
Pulsipher KJ, Presley CL, Waller JD, Szeto MD, Laughter MR, Dellavalle RP.
J Drugs Dermatol. 2021 Mar 1;20(3):351-352. doi: 10.36849/JDD.2021.5899. Review / commentary.
https://doi.org/10.36849/jdd.2021.5899
Herpes zoster following inactivated COVID-19 vaccine: a coexistence or coincidence?
Bostan E, Yalici-Armagan B.
J Cosmet Dermatol. 2021 Feb 27. doi: 10.1111/jocd.14035. Online ahead of print. Case report.
https://doi.org/10.1111/jocd.14035
The safety profile of hydroxychloroquine: major cutaneous and extracutaneous adverse events.
Gisondi P, Piaserico S, Bordin C, Bellinato F, Tozzi F, Alaibac M, Girolomoni G, Naldi L.
Clin Exp Rheumatol. 2021 Feb 15. Online ahead of print. Review.
https://pubmed.ncbi.nlm.nih.gov/33635229/
Hydroxychloroquine-induced acute generalized exanthematous pustulosis: an adverse reaction to keep in mind during COVID-19 pandemic.
Sánchez-Velázquez A, Arroyo-Andrés J, Falkenhain-López D, Peralto JLR, Romero PLO, Díaz RR, Calleja-Algarra A.
J Dtsch Dermatol Ges. 2021 Feb 22. doi: 10.1111/ddg.14354. Online ahead of print. Case reports.
https://doi.org/10.1111/ddg.14354
Morbilliform rash after administration of Pfizer-BioNTech COVID-19 mRNA vaccine.
Jedlowski PM, Jedlowski MF.
Dermatol Online J. 2021 Jan 15;27(1):13030/qt4xs486zg. Case report.
https://escholarship.org/uc/item/4xs486zg
Clearance of longstanding treatment-resistant warts during covid-19 in a transplant recipient.
Erkayman MH, Bilen H.
Transpl Infect Dis. 2021 Jan 28:e13572. doi: 10.1111/tid.13572. Online ahead of print. Case report.
https://doi.org/10.1111/tid.13572
A finding associated with favipiravir-associated photosensitivity: yellow-green fluorescence in the lunulae, scalp, and face.
Çağrı T, Nurcan M.
Dermatol Ther. 2021 Jan 26:e14812. doi: 10.1111/dth.14812. Online ahead of print. Case report & commentary.
https://doi.org/10.1111/dth.14812
Exacerbation of psoriasis following hydroxychloroquine in a patient with suspected COVID-19.
Öncü INS, Güler D, Gürel G.
Dermatol Ther. 2021 Jan 24:e14806. doi: 10.1111/dth.14806. Online ahead of print. Case report.
https://doi.org/10.1111/dth.14806
Oral ivermectin for a scabies outbreak in a long-term-care facility: Potential value in preventing COVID-19 and associated mortality?
Bernigaud C, Guillemot D, Ahmed-Belkacem A, Grimaldi-Bensouda L, Lespine A, Berry F, Softic L, Chenost C, Do-Pham G, Giraudeau B, Fourati S, Chosidow O.
Br J Dermatol. 2021 Jan 16. doi: 10.1111/bjd.19821. Online ahead of print. Cohort study.
https://doi.org/10.1111/bjd.19821
Hydroxychloroquine in the post-COVID-19 era: will this pandemic upset decades of clinical practice?
Pothen L, Yildiz H, Samnick MM, Yombi JC.
Clin Rheumatol. 2021 Jan 15. doi: 10.1007/s10067-020-05572-9. Online ahead of print. Review.
https://doi.org/10.1007/s10067-020-05572-9
Development of toxic epidermal necrolysis in a coronavirus disease 2019 patient with recurrence of positive SARS-CoV-2 viral RNA.
Tanaka A, Isei M, Kikuzawa C, Hinogami H, Nishida K, Gohma I, Ogawa Y.
J Dermatol. 2021 Jan 13. doi: 10.1111/1346-8138.15753. Online ahead of print. Case report.
https://doi.org/10.1111/1346-8138.15753
Chronic hydroxychloroquine therapy and COVID-19 outcomes: A retrospective case-control analysis.
Rangel LK, Shah P, Lo Sicco K, Caplan AS, Femia A.
J Am Acad Dermatol. 2021 Jan 10:S0190-9622(21)00110-9. doi: 10.1016/j.jaad.2020.10.098. Online ahead of print. Case-control study.
https://doi.org/10.1016/j.jaad.2020.10.098
Fluorescence of nails and hair on Wood's lamp examination in covid pandemic; undefined effect of favipiravir in humans.
Aslan Kayıran M, Cebeci F, Erdemir VA, Aksoy H, Akdeniz N, Gürel MS.
Dermatol Ther. 2021 Jan 6:e14740. doi: 10.1111/dth.14740. Online ahead of print. Case series & commentary.
https://doi.org/10.1111/dth.14740
Acute generalized exanthematous pustulosis (AGEP) in 12 patients treated for SARS-CoV-2 positive pneumonia.
Pezzarossa E, Ungari M, Caresana G, Sagradi F, Cimardi L, Pan A, Testa S, Aguggini S, Varotti E, Tanzi G, Manotti L, Ferrero G, Gusolfino MD, Trombatore M; CreSCO Study Group.
Am J Dermatopathol. 2021 Jan 5;Publish Ahead of Print. doi: 10.1097/DAD.0000000000001819. Online ahead of print. Case series.
https://doi.org/10.1097/dad.0000000000001819
Follow-up of skin lesions during COVID-19: a description of a DRESS case.
Brunasso AMG, Castellaneta M, Pontali E, Raggi F, Massone C.
Arch Dermatol Res. 2021 Jan 6. doi: 10.1007/s00403-020-02171-1. Online ahead of print. Case report.
https://doi.org/10.1007/s00403-020-02171-1
Effect of pre-exposure use of hydroxychloroquine on COVID-19 mortality: a population-based cohort study in patients with rheumatoid arthritis or systemic lupus erythematosus using the OpenSAFELY platform.
Rentsch CT, DeVito NJ, MacKenna B, Morton CE, Bhaskaran K, Brown JP, Schultze A, Hulme WJ, Croker R, Walker AJ, Williamson EJ, Bates C, Bacon S, Mehrkar A, Curtis HJ, Evans D, Wing K, Inglesby P, Mathur R, Drysdale H, Wong AYS, McDonald HI, Cockburn J, Forbes H, Parry J, Hester F, Harper S, Smeeth L, Douglas IJ, Dixon WG, Evans SJW, Tomlinson L, Goldacre B.
Lancet Rheumatol. 2020 Nov 5;3(1):e19-27. doi: 10.1016/S2665-9913(20)30378-7. Online ahead of print. Cohort / database study.
https://doi.org/10.1016/s2665-9913(20)30378-7
Tetracyclines in COVID-19 patients quarantined at home: Literature evidence supporting real-world data from a multicenter observational study targeting inflammatory & infectious dermatoses.
Gironi LC, Damiani G, Zavattaro E, Pacifico A, Santus P, Pigatto PDM, Cremona O, Savoia P.
Dermatol Ther. 2020 Dec 22:e14694. doi: 10.1111/dth.14694. Online ahead of print. Prospective cohort study.
https://doi.org/10.1111/dth.14694
Longitudinal melanonychia and skin hyperpigmentation associated with hydroxychloroquine therapy.
Ricardo JW, Chikeka I, Silvers DN, Lipner SR.
JAAD Case Rep. 2020 Nov 6;7:23-25. doi: 10.1016/j.jdcr.2020.10.030. eCollection 2021 Jan. Case report.
https://doi.org/10.1016/j.jdcr.2020.10.030
Effect of hydroxychloroquine pre-exposure on infection with SARS-CoV-2 in rheumatic disease patients: A population-based cohort study.
Jung SY, Kim MS, Kim MC, Choi SH, Chung JW, Choi ST.
Clin Microbiol Infect. 2020 Dec 11:S1198-743X(20)30752-7. doi: 10.1016/j.cmi.2020.12.003. Online ahead of print. Retrospective cohort/case-control study.
https://doi.org/10.1016/j.cmi.2020.12.003
A systematic review on treatment-related mucocutaneous reactions in COVID-19 patients.
Najar Nobari N, Seirafianpour F, Mashayekhi F, Goodarzi A.
Dermatol Ther. 2020 Dec 10. doi: 10.1111/dth.14662. Online ahead of print. Systematic review.
https://doi.org/10.1111/dth.14662
Acute generalized exanthematous pustulosis after COVID-19 infection: A case report from Saudi Arabia.
Alzahrani MJ, Moussa MM, Alfaraj D.
Cureus. 2020 Nov 21;12(11):e11609. doi: 10.7759/cureus.11609. Case report.
https://doi.org/10.7759/cureus.11609
Hydroxychloroquine-related rash in COVID-19 infected patient.
Kurd R, Zuckerman M, Ben-Chetrit E.
Isr Med Assoc J. 2020 Aug;22(8):525. Case report.
https://pubmed.ncbi.nlm.nih.gov/33236590/
Colchicine in dermatology: Rediscovering an old drug with novel uses.
Sardana K, Sinha S, Sachdeva S.
Indian Dermatol Online J. 2020 Sep 19;11(5):693-700. doi: 10.4103/idoj.IDOJ_475_20. eCollection 2020 Sep-Oct. Review.
https://doi.org/10.4103/idoj.idoj_475_20
Hydroxychloroquine use and COVID-19 concerns among alopecia patients: A cross-sectional survey study.
Pathoulas JT, Flanagan KE, Walker CJ, Pupo Wiss I, Hagigeorges D, Senna MM.
Dermatol Ther. 2020 Nov 11. doi: 10.1111/dth.14529. Online ahead of print. Survey / cross-sectional study.
https://doi.org/10.1111/dth.14529
Hydroxychloroquine in patients with rheumatic diseases during the COVID-19 pandemic: a letter to clinicians.
Schreiber K, Sciascia S, Bruce IN, Giles I, Cuadrado MJ, Cohen H, Gordon C, Isenberg D, Jacobsen S, Middeldorp S, Mosca M, Pavord S, Radin M, Roccatello D, Salmon J, Vinet E, Voss A, Watkins L, Hunt BJ.
Lancet Rheumatol. 2020 Oct 29. doi: 10.1016/S2665-9913(20)30382-9. Online ahead of print. Commentary.
https://doi.org/10.1016/s2665-9913(20)30382-9
Acute generalized exanthematous pustulosis and Stevens-Johnson syndrome overlap due to hydroxychloroquine: a case report.
Coleman I, Ruiz G, Brahmbhatt S, Ackerman L.
J Med Case Rep. 2020 Nov 3;14(1):210. doi: 10.1186/s13256-020-02504-8. Case report.
https://doi.org/10.1186/s13256-020-02504-8
Generalized exanthema due to hydroxychloroquine as a popular drug during COVID-19 prophylaxis.
Kutlu O, Özdemir Çetinkaya P, Aktaş H, Metin A.
Int J Clin Pract. 2020 Oct 28:e13793. doi: 10.1111/ijcp.13793. Online ahead of print. Case report.
https://doi.org/10.1111/ijcp.13793
COVID-19: Topical agents and therapeutic prevention of nasal viral acquisition.
Abdelhadi S, Ruszczak Z, Schwartz RA.
Dermatol Ther. 2020 Oct 26. doi: 10.1111/dth.14454. Online ahead of print. Review / commentary.
https://doi.org/10.1111/dth.14454
CD147 inhibitors as a treatment for melanoma: promising agents against SARS-CoV-2 infection.
Pourani MR, Nekooghadam SM, Youssefian L, Vahidnezhad H, Abdollahimajd F.
Dermatol Ther. 2020 Oct 24:e14449. doi: 10.1111/dth.14449. Online ahead of print. Review / commentary.
https://doi.org/10.1111/dth.14449
Delayed presentation of acute generalized exanthematous pustulosis following treatment with cefepime in a patient with COVID-19 without the use of hydroxychloroquine.
Haraszti S, Sendil S, Jensen N.
Am J Case Rep. 2020 Oct 24;21:e926901. doi: 10.12659/AJCR.926901. Case report.
https://doi.org/10.12659/ajcr.926901
Hydroxychloroquine: A comprehensive review and its controversial role in coronavirus disease 2019.
Bansal P, Goyal A, Cusick A, Lahan S, Dhaliwal HS, Bhyan P, Bhattad PB, Aslam F, Ranka S, Dalia T, Chhabra L, Sanghavi D, Sonani B, M Davis J 3rd.
Ann Med. 2020 Oct 23:1-35. doi: 10.1080/07853890.2020.1839959. Online ahead of print. Review.
https://doi.org/10.1080/07853890.2020.1839959
Controversies over hydroxychloroquine in the prevention of SARS-CoV-2 infection put rheumatologists on the frontline.
Bugatti S, De Stefano L, Bobbio-Pallavicini F, Montecucco C.
RMD Open. 2020 Oct;6(3):e001323. doi: 10.1136/rmdopen-2020-001323. Review / commentary.
https://doi.org/10.1136/rmdopen-2020-001323
Acute generalized exanthematous pustulosis with a focus on hydroxychloroquine: A 10-year experience in a skin hospital.
Nili A, Zarei E, Ghamari A, Farid AS, Tavakolpour S, Daneshpazhooh M, Mahmoudi H.
Int Immunopharmacol. 2020 Oct 19;89(Pt B):107093. doi: 10.1016/j.intimp.2020.107093. Online ahead of print. Retrospective cohort study.
https://doi.org/10.1016/j.intimp.2020.107093
Hydroxychloroquine prescribing habits and impact by the COVID-19 pandemic.
Kuraitis D, Murina A.
J Am Acad Dermatol. 2020 Oct 16:S0190-9622(20)32830-9. doi: 10.1016/j.jaad.2020.10.019. Online ahead of print. Survey.
https://doi.org/10.1016/j.jaad.2020.10.019
Thalidomide should be tested as a therapeutic option in COVID-19 pneumonia.
Tiscornia JE, Poggio TV, Feinsilber DG, Coleman AE.
Skinmed. 2020 Aug 1;18(4):254-255. eCollection 2020. Commentary.
https://pubmed.ncbi.nlm.nih.gov/33050993/
Familiar dermatologic drugs as therapies for COVID-19.
Ortega-Peña M, González-Cuevas R.
Actas Dermosifiliogr. 2020 Oct 9:S0001-7310(20)30381-1. doi: 10.1016/j.ad.2020.09.004. Online ahead of print. Review.
https://doi.org/10.1016/j.ad.2020.09.004
A case report of toxic epidermal necrolysis (TEN) in a patient with COVID-19 treated with hydroxychloroquine: are these two partners in crime?
Rossi CM, Beretta FN, Traverso G, Mancarella S, Zenoni D.
Clin Mol Allergy. 2020 Oct 6;18:19. doi: 10.1186/s12948-020-00133-6. eCollection 2020.Case report.
https://doi.org/10.1186/s12948-020-00133-6
Systemic medications of dermatological importance in COVID-19.
Schwartz RA, Sharma A, Szepietowski JC, Sandhu S, Goldust M.
J Drugs Dermatol. 2020 Sep 1;19(9):889-892. doi: 10.36849/JDD.2020.10.36849/JDD.2020.5323. Review.
https://doi.org/10.36849/jdd.2020.10.36849/jdd.2020.5323
Harnessing cooperative immune augmentation by contact allergens to enhance the efficacy of viral vaccines.
Cunningham LS, McFadden JP, Basketter DA, Ferguson FJ, White IR, Kimber I.
Contact Dermatitis. 2020 Aug 9. doi: 10.1111/cod.13685. Online ahead of print. Review / commentary.
https://doi.org/10.1111/cod.13685
Generalized pustular figurate erythema. First report in two COVID-19 patients on hydroxychloroquine.
Abadías-Granado I, Palma-Ruiz AM, Cerro PA, Morales-Callaghan AM, Gómez-Mateo MC, Gilaberte Y, Schwartz RA.
J Eur Acad Dermatol Venereol. 2020 Sep 1. doi: 10.1111/jdv.16903. Online ahead of print.
https://doi.org/10.1111/jdv.16903
Erythema multiforme in the context of SARS-Coronavirus-2 infection.
Sánchez-Velázquez A, Falkenhain D, Rivera Díaz R.
Med Clin (Engl Ed). 2020 Aug 14;155(3):141. doi: 10.1016/j.medcle.2020.04.011. Epub 2020 Jul 2. Case reports.
https://doi.org/10.1016/j.medcle.2020.04.011
Hydroxychloroquine-induced erythema multiforme in a patient with COVID-19.
Serrano JM, Monferrer JC, García-García M, García-Gil MF.
Med Clin (Engl Ed). 2020 Aug 5. doi: 10.1016/j.medcle.2020.05.011. Online ahead of print. Case report.
https://doi.org/10.1016/j.medcle.2020.05.011
COVID-19-related cutaneous manifestations associated with multiple drug sensitization as shown by lymphocyte transformation test.
Hayakawa J, Takakura H, Mizukawa Y, Shiohara T.
J Eur Acad Dermatol Venereol. 2020 Aug 18. doi: 10.1111/jdv.16878. Online ahead of print. Case series / pathololgy study.
https://doi.org/10.1111/jdv.16878
Hydroxychloroquine-related rash in COVID-19 infected patient.
Kurd R, Zuckerman M, Ben-Chetrit E.
Isr Med Assoc J. 2020 Aug;8(22):459. Case report.
https://pubmed.ncbi.nlm.nih.gov/32812725/
Scarcity of hydroxychloroquine and personal protective equipment (PPE) during challenging times of COVID-19 pandemic.
Bhargava S, Rathod D, Singh AK, Rokde R.
Skinmed. 2020 May 1;18(3):188-189. eCollection 2020. Commentary.
https://pubmed.ncbi.nlm.nih.gov/32790620/
Drugs repositioned for COVID-19 are routinely prescribed by dermatologists.
Sharma A, Mhatre M, Goldust M.
Skinmed. 2020 May 1;18(3):186-187. eCollection 2020. Commentary.
https://pubmed.ncbi.nlm.nih.gov/32790618/
Hydroxychloroquine for COVID-19: Myths vs facts.
Kumar S, Sil A, Das A.
Dermatol Ther. 2020 Jun 17:e13857. doi: 10.1111/dth.13857. Online ahead of print. Commentary.
https://doi.org/10.1111/dth.13857
Review of adverse cutaneous reactions of pharmacologic interventions for coronavirus disease 2019 (COVID-19): a guide for the dermatologist.
Martinez-Lopez A, Cuenca-Barrales C, Montero-Vilchez T, Molina-Leyva A, Arias-Santiago S.
J Am Acad Dermatol. 2020 Aug 7:S0190-9622(20)32358-6. doi: 10.1016/j.jaad.2020.08.006. Online ahead of print. Review.
https://doi.org/10.1016/j.jaad.2020.08.006
Androgen sensitivity in COVID-19 and antiandrogens: prospective data are still needed.
Ianhez M, Ramos PM, Goren A, Miot HA.
Dermatol Ther. 2020 Aug 9:e14166. doi: 10.1111/dth.14166. Online ahead of print. Survey / cross-sectional study.
https://doi.org/10.1111/dth.14166
COVID-19 and immunological regulations - from basic and translational aspects to clinical implications.
Schön MP, Berking C, Biedermann T, Buhl T, Erpenbeck L, Eyerich K, Eyerich S, Ghoreschi K, Goebeler M, Ludwig RJ, Schäkel K, Schilling B, Schlapbach C, Stary G, von Stebut E, Steinbrink K.
J Dtsch Dermatol Ges. 2020 Aug 6. doi: 10.1111/ddg.14169. Online ahead of print. Review.
https://doi.org/10.1111/ddg.14169
Hydroxychloroquine-induced hyperpigmentation in a 14-year-old female with systemic lupus erythematosus.
Leung AK, McMillan T, Human A, Lam JM.
Drugs Context. 2020 Jul 20;9:2020-5-8. doi: 10.7573/dic.2020-5-8. eCollection 2020. Case report.
https://doi.org/10.7573/dic.2020-5-8
Drug reaction with eosinophilia and systemic symptoms syndrome in a patient with COVID-19.
Herman A, Matthews M, Mairlot M, Nobile L, Fameree L, Jacquet LM, Baeck M.
J Eur Acad Dermatol Venereol. 2020 Jul 31. doi: 10.1111/jdv.16838. Online ahead of print. Case report.
https://doi.org/10.1111/jdv.16838
Emerging treatments in COVID-19: Adverse drug reactions including drug hypersensitivities.
Manjaly Thomas ZR, Leuppi-Taegtmeyer A, Jamiolkowski D, Steveling-Klein E, Bellutti-Enders F, Hofmeier KS, Hartmann K.
J Allergy Clin Immunol. 2020 Jul 22:S0091-6749(20)31025-3. doi: 10.1016/j.jaci.2020.07.008. Online ahead of print. Review.
https://doi.org/10.1016/j.jaci.2020.07.008
Hydroxychloroquine in dermatology and beyond: Recent update.
Sardana K, Sinha S, Sachdeva S.
Indian Dermatol Online J. 2020 May 10;11(3):453-464. doi: 10.4103/idoj.IDOJ_280_20. eCollection 2020 May-Jun. Review.
http://www.ncbi.nlm.nih.gov/pmc/articles/pmc7367590/
Hydroxychloroquine, dermatology and SARS-CoV-2: Updating an old association.
Diotallevi F, Campanati A, Radi G, Luchetti MM, Benfaremo D, Tagliati C, Simonetti O, Offidani A.
J Med Virol. 2020 Jul 21. doi: 10.1002/jmv.26322. Online ahead of print. Report / commentary.
https://doi.org/10.1002/jmv.26322
First case of DRESS syndrome caused by hydroxychloroquine with a positive patch test.
Jimenez AC, Navarrate Navarrete N, Gratacós Gómez AR, Florido López F, Garcia Rodriguez R, Elisa GT.
Contact Dermatitis. 2020 Jul 12. doi: 10.1111/cod.13657. [Epub ahead of print] No abstract available. Case report.
https://doi.org/10.1111/cod.13657
Retrospective analysis of dermatological adverse events associated with hydroxychloroquine reported to the United States Food and Drug Administration.
Lipner SR, Wang Y.
J Am Acad Dermatol. 2020 Jul 8. pii: S0190-9622(20)32171-X. doi: 10.1016/j.jaad.2020.07.007. [Epub ahead of print] No abstract available. Research study.
https://doi.org/10.1016/j.jaad.2020.07.007
How COVID-19 affects patients receiving anticytokine and JAK inhibitors in rheumatology and dermatology.
Jessica Chang TY, Pope JE.
Immunotherapy. 2020 Jul 9. doi: 10.2217/imt-2020-0153. [Epub ahead of print] No abstract available. Review / commentary.
https://doi.org/10.2217/imt-2020-0153
Angiotensin II receptors - Impact for COVID-19 severity.
Aksoy H, Karadag AS, Wollina U.
Dermatol Ther. 2020 Jul 9:e13989. doi: 10.1111/dth.13989. [Epub ahead of print]. Review.
https://doi.org/10.1111/dth.13989
Potential role of IL-17 blocking agents in the treatment of severe COVID-19?
Bulat V, Situm M, Azdajic MD, Likic R.
Br J Clin Pharmacol. 2020 Jul 5. doi: 10.1111/bcp.14437. [Epub ahead of print] No abstract available. Review / commentary.
https://doi.org/10.1111/bcp.14437
Hydroxychloroquine-induced Stevens-Johnson syndrome in COVID-19: a rare case report.
Davoodi L, Jafarpour H, Kazeminejad A, Soleymani E, Akbari Z, Razavi A.
Oxf Med Case Reports. 2020 Jun 25;2020(6):omaa042. doi: 10.1093/omcr/omaa042. eCollection 2020 Jun. Case report.
https://doi.org/10.1093/omcr/omaa042
Potential use of turmeric in COVID-19.
Gupta H, Gupta M, Bhargava S.
Clin Exp Dermatol. 2020 Jul 1. doi: 10.1111/ced.14357. [Epub ahead of print]. Commentary.
https://doi.org/10.1111/ced.14357
Colchicin treatment of Covid-19 presenting with cutaneous rash and myopericarditis.
Recalcati S, Piconi S, Franzetti M, Barbagallo T, Prestinari F, Fantini F.
Dermatol Ther. 2020 Jun 25. doi: 10.1111/dth.13891. [Epub ahead of print] No abstract available. Case report.
https://doi.org/10.1111/dth.13891
Considerations of managing lichen planopilaris with hydroxychloroquine during the COVID-19 pandemic.
Dadkhahfar S, Araghi F, Tabary M, Moravvej H.
J Drugs Dermatol. 2020 Jun 1;19(6):679-680. No abstract available. Review / commentary.
https://jddonline.com/articles/dermatology/S1545961620P0679X
Biologics and small molecules in the treatment of COVID-19.
Murrell DF, Rudnicka L, Shivakumar S, Kassir M, Jafferany M, Galadari H, Lotti T, Sadoughifar R, Sitkowska Z, Goldust M.
J Drugs Dermatol. 2020 Jun 1;19(6):673-675. No abstract available. Review / commentary.
https://jddonline.com/articles/dermatology/S1545961620P0673X
Cutaneous side effects of hydroxychloroquine in health care workers in a COVID referral hospital - implications for clinical practice.
Sardana K, Mathachan SR, Deepak D, Khurana A, Sinha S.
J Dermatolog Treat. 2020 Jun 22:1-3. doi: 10.1080/09546634.2020.1781041. [Epub ahead of print]. Case reports.
https://doi.org/10.1080/09546634.2020.1781041
Utility and risk of dermatologic medications during the COVID-19 pandemic.
Goldust M, Hartmann K, Abdelmaksoud A, Navarini AA.
Dermatol Ther. 2020 Jun 15. doi: 10.1111/dth.13833. [Epub ahead of print]. Review.
https://doi.org/10.1111/dth.13833
Treatment of Covid19 - Repurposing drugs commonly used in dermatology.
Stojkovic-Filipovic J, Bosic M.
Dermatol Ther. 2020 Jun 15. doi: 10.1111/dth.13829. [Epub ahead of print]. Review.
https://doi.org/10.1111/dth.13829
Comment on "Generalized pustular figurate erythema: A newly delineated severe cutaneous drug reaction linked with hydroxychloroquine": report of a COVID-19 patient with particular findings.
Suarez-Valle A, Fernandez-Nieto D, Melian-Olivera A, Dominguez-Santas M, Diaz-Guimaraens B, Del Real CMG, Jimenez-Cauhe J.
Dermatol Ther. 2020 Jun 16:e13852. doi: 10.1111/dth.13852. [Epub ahead of print] No abstract available. Commentary.
https://doi.org/10.1111/dth.13852
Acute generalized exanthematous pustulosis induced by empiric hydroxychloroquine for presumed COVID-19.
Enos T, Jeong HS, Vandergriff T, Jacobe HT, Chong BF.
Dermatol Ther. 2020 Jun 15. doi: 10.1111/dth.13834. [Epub ahead of print] No abstract available. Case report.
https://doi.org/10.1111/dth.13834
Further aspects of doxycycline therapy in COVID-19.
Szolnoky G.
Dermatol Ther. 2020 Jun 13:e13810. doi: 10.1111/dth.13810. [Epub ahead of print] No abstract available. Commentary.
https://doi.org/10.1111/dth.13810
Dermatological therapies with relevance to COVID-19.
Shishak M, Sarkar R.
Dermatol Ther. 2020 Jun 11:e13813. doi: 10.1111/dth.13813. [Epub ahead of print]. Review / commentary.
https://doi.org/10.1111/dth.13813
Acute generalized exanthematous pustulosis induced by hydroxychloroquine prescribed for COVID-19.
Delaleu J, Deniau B, Battistella M, de Masson A, Bensaid B, Jachiet M, Lazaridou I, Bagot M, Bouaziz JD; Saint-Louis CORE (COvid REsearch) group.
J Allergy Clin Immunol Pract. 2020 Jun 7. pii: S2213-2198(20)30587-0. doi: 10.1016/j.jaip.2020.05.046. [Epub ahead of print] No abstract available. Case report.
https://doi.org/10.1016/j.jaip.2020.05.046
Hydroxychloroquine-induced erythema multiforme in a patient with COVID-19.
Monte Serrano J, Cruañes Monferrer J, García-García M, García-Gil MF.
Med Clin (Barc). 2020 May 19. pii: S0025-7753(20)30280-3. doi: 10.1016/j.medcli.2020.05.004. [Epub ahead of print] English, Spanish. No abstract available. Case report.
https://doi.org/10.1016/j.medcli.2020.05.004
Omalizumab and COVID19 treatment: Could it help?
Abdelmaksoud A, Goldust M, Vestita M.
Dermatol Ther. 2020 Jun 8:e13792. doi: 10.1111/dth.13792. [Epub ahead of print] No abstract available. Review / commentary.
https://doi.org/10.1111/dth.13792
Azithromycin and COVID-19. Prompt early use at first signs of this infection in adults and children: an approach worthy of consideration.
Schwartz RA, Suskind RM.
Dermatol Ther. 2020 Jun 8:e13785. doi: 10.1111/dth.13785. [Epub ahead of print]. Commentary.
https://doi.org/10.1111/dth.13785
Back to the basics: Propolis and COVID-19.
Bachevski D, Damevska K, Simeonovski V, Dimova M.
Dermatol Ther. 2020 Jun 7:e13780. doi: 10.1111/dth.13780. [Epub ahead of print] No abstract available. Review / commentary.
https://doi.org/10.1111/dth.13780
Advances in skin science enable the development of a COVID-19 vaccine.
Falo LD Jr.
J Am Acad Dermatol. 2020 May 30. pii: S0190-9622(20)31002-1. doi: 10.1016/j.jaad.2020.05.126. [Epub ahead of print] No abstract available. Commentary.
https://doi.org/10.1016/j.jaad.2020.05.126
Potential role of Anti-IL-17 in COVID-19 treatment.
Ayhan E, Öztürk M, An İ, Abdelmaksoud A, Araç E.
Dermatol Ther. 2020 May 30:e13715. doi: 10.1111/dth.13715. [Epub ahead of print] No abstract available. Commentary.
https://doi.org/10.1111/dth.13715
Treatment of COVID-19 with pentoxifylline: Could it be a potential adjuvant therapy?
Seirafianpour F, Mozafarpoor S, Fattahi N, Sadeghzadeh-Bazargan A, Hanifiha M, Goodarzi A.
Dermatol Ther. 2020 May 30. doi: 10.1111/dth.13733. [Epub ahead of print]. Review.
https://doi.org/10.1111/dth.13733
Prescription restrictions on hydroxychloroquine among the largest Florida pharmacy chains during the COVID-19 pandemic: An observational study.
Hadeler E, Bray F.
J Am Acad Dermatol. 2020 May 22. pii: S0190-9622(20)30964-6. doi: 10.1016/j.jaad.2020.05.092. [Epub ahead of print] No abstract available. Observational study.
https://doi.org/10.1016/j.jaad.2020.05.092
Hydroxychloroquine effects on psoriasis: a systematic review and a cautionary note for COVID-19 treatment.
Sachdeva M, Mufti A, Maliyar K, Lytvyn Y, Yeung J.
J Am Acad Dermatol. 2020 May 19. pii: S0190-9622(20)30942-7. doi: 10.1016/j.jaad.2020.05.074. [Epub ahead of print]. Systematic review.
https://doi.org/10.1016/j.jaad.2020.05.074
Dermatologic manifestations of hydroxychloroquine therapy: a closer look at the nails.
Lipner SR, Scher RK.
J Am Acad Dermatol. 2020 May 18. pii: S0190-9622(20)30929-4. doi: 10.1016/j.jaad.2020.04.177. [Epub ahead of print] No abstract available. Commentary / review.
https://doi.org/10.1016/j.jaad.2020.04.177
Hydroxychloroquine shortages during the COVID-19 pandemic.
Mendel A, Bernatsky S, Thorne JC, Lacaille D, Johnson SR, Vinet É.
Ann Rheum Dis. 2020 May 20. pii: annrheumdis-2020-217835. doi: 10.1136/annrheumdis-2020-217835. [Epub ahead of print] No abstract available. Survey.
https://doi.org/10.1136/annrheumdis-2020-217835
The COVID-19 chemoprophylactic conundrum - Are we limiting available resources?
Sharma A, Mhatre M, Goldust M, Jindal V, Singla P.
Dermatol Ther. 2020 May 17:e13607. doi: 10.1111/dth.13607. [Epub ahead of print] No abstract available. Survey.
https://doi.org/10.1111/dth.13607
Acute generalized exanthematous pustulosis after COVID-19 treatment with hydroxychloroquine.
Litaiem N, Hajlaoui K, Karray M, Slouma M, Zeglaoui F.
Dermatol Ther. 2020 May 13:e13565. doi: 10.1111/dth.13565. [Epub ahead of print] No abstract available. Case report.
https://doi.org/10.1111/dth.13565
Systemic immunobiological, immunosuppressant and oncologic agents for the treatment of dermatologic diseases during the SARS-Cov-2 (COVID19) pandemic emergency: A quick review for a quick consultation.
Paolino G, Mercuri SR, Bearzi P, Mattozzi C.
Dermatol Ther. 2020 May 8:e13537. doi: 10.1111/dth.13537. [Epub ahead of print]. Review.
https://doi.org/10.1111/dth.13537
Acute generalized exanthematous pustulosis with erythema multiforme-like lesions in a COVID-19 woman.
Robustelli Test E, Vezzoli P, Carugno A, Raponi F, Gianatti A, Rongioletti F, Sena P.
J Eur Acad Dermatol Venereol. 2020 May 9. doi: 10.1111/jdv.16613. [Epub ahead of print]. Case report.
https://doi.org/10.1111/jdv.16613
The impact of hydroxychloroquine shortages on patients with dermatological conditions during COVID-19 pandemic.
Shah M, Sachdeva M, Dodiuk-Gad RP.
Dermatol Ther. 2020 May 7. doi: 10.1111/dth.13524. [Epub ahead of print] No abstract available. Letter / commentary.
https://doi.org/10.1111/dth.13524
Can hydroxychloroquine be useful in the prevention of COVID-19? An Italian survey in dermatological and rheumatological patients already under treatment.
Vastarella M, Patrì A, Annunziata MC, Cantelli M, Nappa P, Tasso M, Costa L, Caso F, Fabbrocini G.
J Am Acad Dermatol. 2020 Apr 30. pii: S0190-9622(20)30757-X. doi: 10.1016/j.jaad.2020.04.136. [Epub ahead of print] No abstract available. Survey.
https://doi.org/10.1016/j.jaad.2020.04.136
Drug reaction with eosinophilia and systemic symptoms syndrome to hydroxychloroquine, an old drug in the spotlight.
Grandolfo M, Romita P, Bonamonte D, Cazzato G, Hansel K, Stingeni L, Conforti C, Giuffrida R, Foti C.
Dermatol Ther. 2020 May 2. doi: 10.1111/dth.13499. [Epub ahead of print] No abstract available. Case report.
https://doi.org/10.1111/dth.13499
Cutaneous side-effects of the potential Covid-19 drugs.
Türsen Ü, Türsen B, Lotti T.
Dermatol Ther. 2020 May 1:e13476. doi: 10.1111/dth.13476. [Epub ahead of print]. Review.
https://doi.org/10.1111/dth.13476
Risks of hydroxychloroquine use for COVID-19 prophylaxis.
Sachdeva M, Shah M, Ziv M, Leshem E, Dodiuk-Gad RP.
J Am Acad Dermatol. 2020 Apr 26. pii: S0190-9622(20)30727-1. doi: 10.1016/j.jaad.2020.04.111. [Epub ahead of print] No abstract available. Letter.
https://doi.org/10.1016/j.jaad.2020.04.111
Response to "Risks of Hydroxychloroquine use for COVID-19 prophylaxis".
Grant-Kels JM.
J Am Acad Dermatol. 2020 Apr 26. pii: S0190-9622(20)30728-3. doi: 10.1016/j.jaad.2020.04.112. [Epub ahead of print] No abstract available. Letter.
https://doi.org/10.1016/j.jaad.2020.04.112
Clinical course of coronavirus disease 2019 (COVID-19) in a series of 17 patients with systemic lupus erythematosus under long-term treatment with hydroxychloroquine.
Mathian A, Mahevas M, et al.
Ann Rheum Dis. 2020 Apr 24. pii: annrheumdis-2020-217566. doi: 10.1136/annrheumdis-2020-217566. [Epub ahead of print] No abstract available. Case series.
https://doi.org/10.1136/annrheumdis-2020-217566
Applying the ethical principles of resource allocation to drugs in limited supply during a public health crisis.
Kong HE, Grant-Kels JM, Stoff BK.
J Am Acad Dermatol. 2020 Apr 21. pii: S0190-9622(20)30693-9. doi: 10.1016/j.jaad.2020.04.078. [Epub ahead of print] No abstract available. Commentary / review.
https://doi.org/10.1016/j.jaad.2020.04.078
Dermatoethics: Self-prescribing Plaquenil during the COVID-19 pandemic.
Stoj VJ, Grant-Kels JM.
Int J Womens Dermatol. 2020 Apr 23. doi: 10.1016/j.ijwd.2020.04.006. [Epub ahead of print] No abstract available. Commentary / review.
https://doi.org/10.1016/j.ijwd.2020.04.006
A systematic review of the prophylactic role of chloroquine and hydroxychloroquine in Coronavirus Disease-19 (COVID-19).
Shah S, Das S, Jain A, Misra DP, Negi VS.
Int J Rheum Dis. 2020 Apr 13. doi: 10.1111/1756-185X.13842. [Epub ahead of print]. Systematic review.
https://doi.org/10.1111/1756-185X.13842
Is there a future for hydroxychloroquine/chloroquine in prevention of SARS-CoV-2 infection (COVID-19)?
Moiseev S, Avdeev S, Brovko M, Novikov P, Fomin V.
Ann Rheum Dis. 2020 Apr 21. pii: annrheumdis-2020-217570. doi: 10.1136/annrheumdis-2020-217570. [Epub ahead of print] No abstract available. Letter.
https://doi.org/10.1136/annrheumdis-2020-217570
Doxycycline, a widely used antibiotic in dermatology with a possible anti-inflammatory action against IL-6 in COVID-19 outbreak.
Conforti C, Giuffrida R, Zalaudek I, Di Meo N.
Dermatol Ther. 2020 Apr 20:e13437. doi: 10.1111/dth.13437. [Epub ahead of print] No abstract available. Letter.
https://doi.org/10.1111/dth.13437
Characterizing the adverse dermatologic effects of hydroxychloroquine: a systematic review.
Sharma AN, Mesinkovska NA, Paravar T.
J Am Acad Dermatol. 2020 Apr 11. pii: S0190-9622(20)30564-8. doi: 10.1016/j.jaad.2020.04.024. [Epub ahead of print]. Systematic review.
https://doi.org/10.1016/j.jaad.2020.04.024
Coalition: Advocacy for prospective clinical trials to test the post-exposure potential of hydroxychloroquine against COVID-19.
Picot S, Marty A, Bienvenu AL, Blumberg LH, Dupouy-Camet J, Carnevale P, Kano S, Jones MK, Daniel-Ribeiro CT, Mas-Coma S.
One Health. 2020 Apr 4:100131. doi: 10.1016/j.onehlt.2020.100131. [Epub ahead of print]. Editorial.
https://doi.org/10.1016/j.onehlt.2020.100131
Hydroxychloroquine and ivermectin: a synergistic combination for COVID-19 chemoprophylaxis and/or treatment?
Patrì A, Fabbrocini G.
J Am Acad Dermatol. 2020 Apr 10. pii: S0190-9622(20)30557-0. doi: 10.1016/j.jaad.2020.04.017. [Epub ahead of print] No abstract available. Letter.
https://doi.org/10.1016/j.jaad.2020.04.017
Does hydroxychloroquine combat COVID-19? A timeline of evidence.
Alia E, Grant-Kels JM.
J Am Acad Dermatol. 2020 Apr 10. pii: S0190-9622(20)30607-1. doi: 10.1016/j.jaad.2020.04.031. [Epub ahead of print] No abstract available. Review / commentary.
https://doi.org/10.1016/j.jaad.2020.04.031
Generalized pustular figurate erythema a newly delineated severe cutaneous drug reaction linked with hydroxychloroquine.
Schwartz RA, Janniger CK.
Dermatol Ther. 2020 Apr 6. doi: 10.1111/dth.13380. [Epub ahead of print]. Review / commentary.
https://www.ncbi.nlm.nih.gov/pubmed/32253799
A case of exacerbation of psoriasis after oseltamivir and hydroxychloroquine in a patient with COVID-19: Will cases of psoriasis increase after COVID-19 pandemic?
Kutlu Ö, Metin A.
Dermatol Ther. 2020 Apr 7:e13383. doi: 10.1111/dth.13383. [Epub ahead of print] No abstract available. Case report.
https://doi.org/10.1111/dth.13383
Use of hydroxychloroquine and chloroquine during the COVID-19 pandemic: What every clinician should know.
Yazdany J, Kim AHJ.
Ann Intern Med. 2020 Mar 31. doi: 10.7326/M20-1334. [Epub ahead of print] No abstract available. Commentary.
https://doi.org/10.7326/M20-1334
The use of anti-inflammatory drugs in the treatment of people with severe coronavirus disease 2019 (COVID-19): The experience of clinical immunologists from China.
Zhang W, Zhao Y, Zhang F, Wang Q, Li T, Liu Z, Wang J, Qin Y, Zhang X, Yan X, Zeng X, Zhang S.
Clin Immunol. 2020 Mar 25:108393. doi: 10.1016/j.clim.2020.108393. [Epub ahead of print] Review.
https://doi.org/10.1016/j.clim.2020.108393
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
Gautret P, Lagier JC, Parola P, Hoang VT, Meddeb L, Mailhe M, Doudier B, Courjon J, Giordanengo V, Vieira VE, Dupont HT, Honoré S, Colson P, Chabrière E, La Scola B, Rolain JM, Brouqui P, Raoult D.
Int J Antimicrob Agents. 2020 Mar 20:105949. doi: 10.1016/j.ijantimicag.2020.105949. [Epub ahead of print]. Clinical trial.
https://www.ncbi.nlm.nih.gov/pubmed/32205204
A systematic review on the efficacy and safety of chloroquine for the treatment of COVID-19.
Cortegiani A, Ingoglia G, Ippolito M, Giarratano A, Einav S.
J Crit Care. 2020 Mar 10. pii: S0883-9441(20)30390-7. doi: 10.1016/j.jcrc.2020.03.005. [Epub ahead of print]. Systematic review.
https://www.ncbi.nlm.nih.gov/pubmed/32173110
Back to CEBD Coronavirus Dermatology Resource Homepage